Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)

The summary for the Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional): This Funding Opportunity Announcement (FOA) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying SUD, including fundamental brain function relevant to substance use. This FOA is particularly designed to support exploratory/developmental projects requiring budgets that would exceed that allowed for the R21 mechanism (Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional)

Federal Grant Title:	Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-23-157
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Information not provided
Current Application Deadline:	May 7th, 2026
Original Application Deadline:	May 7th, 2026
Posted Date:	April 10th, 2023
Creation Date:	April 10th, 2023
Archive Date:	June 12th, 2026
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	April 10th, 2023

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/pa-files/PAR-23-157.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and P...; • Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Tri...; • Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/...; • Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not ...; • Ex Vivo Models for Studies at the Intersection of HIV and Addictive Substance Use (R01 Cli...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • Time-Sensitive Evaluation of Policies Affecting Health Behaviors and Chronic Disease Risk ...; • NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements...; • Single Source: Bench to Bassinet Congenital Heart disease Advancing New understanding in G...; • NIDCD Research Dissertation Fellowship for Au.D. Audiologists (F32); • NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)